Thrive With Type 1 Diabetes: A Behavioral Program to Improve Glucose and Sleep
Official title: Intervention to Thrive With Type 1 Diabetes 2026
Run by Emory University · NCT07522866 · Data updated 2026-11-12
A behavioral program is being tested to see if it helps adults with type 1 diabetes better manage their sleep and glucose targets.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 31 Years to 75 Years |
| Sex | All |
| Enrollment | 48 (estimated) |
| Sponsor | Emory University Academic / other |
| Locations | 2 sites (Atlanta, Georgia and 1 other locations) |
| Status | Recruiting |
| Started | September 2026 |
| Main results expected | April 2028 |
| Study ends | April 2028 |
| Registry record updated | August 6, 2026 |
| Trial ID | NCT07522866 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 31–75 with type 1 diabetes for at least one year who have one or more out-of-range sleep health measures.
✕Probably not a fit
Participants without sleep-related issues or those unlikely to respond to behavioral approaches may see limited benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study explores whether a cognitive behavioral intervention can help adults with type 1 diabetes improve self-management and reach glucose targets. Participants will be assigned to either the TranS-C Intervention Arm or an Attention Control Enhanced Usual Care arm. The study focuses on adults aged 31–75 with type 1 diabetes who have at least one out-of-range sleep health measure and will be conducted at Emory University and affiliated nursing and medical facilities. Outcomes are centered on glycemic control and sleep quality, with potential implications for reducing vascular risk associated with suboptimal management. The trial is led by Emory University with no listed collaborators beyond the institution itself.
Why it matters
Potential benefit: If successful, participants could experience better blood sugar control and sleep, which may reduce long-term diabetes complications.
How similar studies have gone: Previous behavioral approaches show promise for improving self-management and sleep in chronic conditions, but this specific TranS-C strategy in type 1 diabetes is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 31 to 75 years * Type 1 Diabetes for at least 1 year * One or more sleep health dimensions are out of range Exclusion Criteria: * Non-English speaking * Recent night shift work or transmeridian travel * Life-limiting illness
Where it's running
-
Emory University, Nell Hodgson Woodruff School of Nursing
Atlanta, Georgia, United States Recruiting -
Emory University
Atlanta, Georgia, United States Recruiting
Study contacts
- Principal investigator: Stephanie Griggs, PhD, RN, FAAN — Emory University
- Study coordinator: Stephanie Griggs, PhD, RN, FAAN
- Email: stephanie.griggs2@emory.edu
- Phone: 404-544-9915
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Continuous Glucose Monitor Accuracy and Safety in Adults with Type 1 Diabetes
This study tests a new real-time CGM system in adults with type 1 diabetes to see if its readings match venous blood glucose measurements.
-
Cardiometabolic effects of non-nutritive sweeteners in Type 1 diabetes
This study tests whether non-nutritive sweeteners in a 12-ounce cherry Gatorade drink affect blood sugar control and cardiovascular markers in teens and young adults with Type 1 diabetes.
-
Wearable continuous glucose and ketone monitor for adults with type 1 diabetes
This trial will test if a new wearable device can continuously and accurately measure glucose and ketone levels in adults with type 1 diabetes.
-
Tirzepatide for obesity in people with type 1 diabetes
This trial will test whether tirzepatide helps adults with type 1 diabetes and obesity lose weight and is safe for them.
-
New real-time continuous glucose monitor accuracy and safety in adults with type 1 diabetes
This project will test a new real-time continuous glucose monitor to see if its sensor readings match lab venous plasma (YSI) measurements in adults with type 1 diabetes.
-
Dapagliflozin, Pioglitazone, and Ketone Production in Type 1 Diabetes
This study tests whether adding pioglitazone to dapagliflozin in adults with type 1 diabetes can lessen liver glucose production, fat breakdown, and ketone production while on insulin.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.